INDV — Indivior Pharmaceuticals Inc

Indivior PLC Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Net Revenue: $314 million, up 2% year-over-year.
• SUBLOCADE Net Revenue: $219 million, a 15% increase from Q3 2024, driven by an 8% growth in dispense volume.
• Adjusted EBITDA: $120 million, a 14% increase year-over-year.
• Operating Expenses: Non-GAAP operating expenses were $145 million, down 3% from the previous year.
• Cash Position: Gross cash and investments increased to $473 million, up from $347 million at year-end 2024.

2. Strategic Updates and Business Highlights

• Indivior is progressing with its Indivior Action Agenda, focusing on simplifying operations and enhancing commercial execution, particularly for SUBLOCADE.
• The company has implemented cost-saving measures expected to reduce operating expenses by at least $150 million annually starting in 2026.
• A new direct-to-consumer campaign, "Move Forward in Recovery," was launched to raise awareness of SUBLOCADE.
• The organization has streamlined operations, including the cancellation of its London Stock Exchange listing and restructuring R&D and medical affairs.

3. Forward Guidance and Outlook

• Raised 2025 Financial Guidance: Total net revenue is now expected to be between $1.18 billion and $1.22 billion, with SUBLOCADE net revenue projected at $825 million to $845 million (10% growth at midpoint).
• Adjusted EBITDA Guidance: Increased to $400 million to $420 million, reflecting a 15% growth versus 2024.
• The company plans to provide full-year 2026 financial guidance in early January 2026, with expectations for increased profitability and cash generation.

4. Bad News, Challenges, or Points of Concern

• Pricing Pressure: While SUBOXONE Film pricing has stabilized, there are ongoing concerns regarding market dynamics and potential future price erosion.
• Operational Complexity: The organization is undergoing significant restructuring, which could pose risks during the transition period.
• Market Competition: Although SUBLOCADE holds a 75% market share in the LAI category, the overall market penetration remains low at 8%, indicating room for growth but also competitive pressures.

5. Notable Q&A Insights

• Cost Reduction Breakdown: The $150 million in operating expense cuts primarily stem from a 32% reduction in headcount, discontinuation of OPVEE marketing, and optimization of the Rest of World business.
• Commercial Strategy: The focus is on improving commercial execution across both Medicaid and commercial channels, with an emphasis on increasing the number of prescribers and their patient loads.
• R&D Spending: Future R&D expenditures will be streamlined, with preserved capabilities to advance Phase II assets into Phase III if warranted.
• Market Growth: There is optimism regarding SUBLOCADE's growth trajectory, with indications that improved commercial execution and label updates are positively impacting prescribing patterns.

Overall, Indivior's Q3 2025 results reflect a solid performance, driven by SUBLOCADE's growth, while the company prepares for a strategic transition into a new phase aimed at accelerating growth and profitability.